1. Jacobson I, Lawitz E, Kwo P, et al. An Integrated analysis of 402 compensated cirrhotic patients with HCV genotype (GT) 1, 4 or 6 infection treated with Elbasvir/Grazoprevir. AASLD 2015. Abstract 42.
  2. Rockstroh JK, Nelson M, Katlama C, et al. High efficacy of GRZ/EBR(GZR/EBR) in HCV genotype 1, 4, and 6-infected patients with HIV coinfection: SVR24 data from the phase 3 C-EDGE Coinfection study. AASLD 2015. Abstract 210.
  3. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015; 163:1-13.
  4. Kwo P, Gane E, Peng CY, et al. Efficacy and safety of GRZ/EBR ± RBV for 12 or 16 weeks in patients with HCV G1, G4, or G6 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced. EASL 2015. Abstract P0886.
  5. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015; 2:e319-e327.
  6. Dore GJ, Altice F, Litwin AH, et al, C-EDGE CO-STAR: efficacy of grazoprevir/elbasvir Fixed Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy. AASLD 2015. Abstract 40.
  7. Fabrizi F, Dixit V,Messa P. Impact of hepatitis C on survival in dialysis patients: a linkwith cardiovascularmortality? J Viral Hepat 2012; 19:601-07.
  8. Park H, Adeyemi A, Henry L, et al. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitisC virus infection. J Viral Hepat. 2015 Nov; 22(11):897-905.
  9. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015; 386:1537-45.
  10. Yeh WW, Caro C, Guo Z, et al. Pharmacokinetics of Co-Administered HCV Protease Inhibitor Grazoprevir (MK-5172) and NS5A Inhibitor Elbasvir (MK-8742) in Volunteers With End-Stage Renal Disease on Hemodialysis or Severe Renal Impairment Not on Hemodialysis. AASLD 2014. Poster 1940.
  11. Ferrante S, Elbasha EH, Greaves W, et al. Projected Long-term impact of Grazoprevir (GZR, MK-5172)/Elbasvir (EBR, MK-8742) in Treatment-naive and Treatment-experienced Patients with Hepatic C Virus Genotype 1 infection and Chronic Kidney Disease. AASLD 2015. Abstract 727.
© Effetti srl